The global
digital biomarkers market is set to witness a growth rate of
20% in the next 5 years. Rising prevalence of chronic diseases,
growing adoption of wearables and smart devices, shift toward personalized and
preventive healthcare, advancements in AI and machine learning, and
pharmaceutical industry’s demand for efficient clinical trials, are some of the
key factors driving the digital biomarkers market.
Digital biomarkers are objective, quantifiable
physiological and behavioral data collected and measured through digital
devices such as smartphones, wearables, and sensors. These biomarkers are used
to monitor, predict, or diagnose health conditions in real time, providing
continuous insights into a patient’s status outside traditional clinical
settings. They are particularly useful in chronic disease management, mental
health, and neurodegenerative disorders among others. Unlike traditional
biomarkers that often require lab-based tests, digital biomarkers enable
passive, non-invasive data collection. Advances in artificial intelligence and
data analytics further enhance their utility, making them valuable tools for
personalized medicine, remote monitoring, and efficient clinical trial design.
Download a free sample report now 👉
https://meditechinsights.com/digital-biomarkers-market/request-sample/
Growing adoption of wearables and smart devices to propel
market demand
The growing adoption of wearables and smart devices is a
major driver of the digital biomarkers market. Devices like smartwatches,
fitness trackers, and mobile health apps enable continuous, real-time
monitoring of physiological and behavioral data such as heart rate, sleep
patterns, activity levels, and more. This constant data flow allows for early
detection of health anomalies and supports proactive, personalized healthcare.
As consumers become more health-conscious and comfortable with digital technologies,
the widespread use of these devices fuels demand for digital biomarkers.
Additionally, their integration with cloud platforms and AI analytics enhances
clinical decision-making and supports remote patient monitoring.
Digital biomarkers powering the shift to decentralized
clinical trials
The growth of remote and decentralized clinical trials is a
key trend driving the digital biomarkers market. These trials leverage digital
biomarkers to collect continuous, real-time patient data outside traditional
clinical settings, reducing the need for in-person visits. This approach
enhances patient recruitment, retention, and compliance while lowering
operational costs. Wearables, mobile apps, and sensors enable seamless remote
monitoring, making trials more inclusive and geographically flexible. As regulatory
bodies increasingly recognize digital endpoints, the adoption of decentralized
trial models is accelerating, positioning digital biomarkers as essential tools
in transforming clinical research into a more patient-centric process.
Competitive Landscape Analysis
The global digital biomarkers market is marked by the
presence of established and emerging market players such as BioSensics,
ActiGraph, LLC; AliveCor, Inc.; Koneksa Health; Altoida; Amgen Inc.;
Biogen; Empatica Inc.; IXICO plc; Neurotrack Technologies, Inc.; among
others. Some of the key strategies adopted by market players include new
product development, strategic partnerships and collaborations, and geographic
expansion.
Download a sample report for in-depth competitive
insights
https://meditechinsights.com/digital-biomarkers-market/request-sample/
Global Digital Biomarkers Market Segmentation
This report by Medi-Tech Insights provides the size of
the global digital biomarkers market at the regional- and country-level
from 2023 to 2030. The report further segments the market based on product,
application, therapeutic area, end user.
Market Size & Forecast (2023-2030), By Product, USD
Million
- Wearable
Devices
- Mobile
Applications
- Sensors
- Software
& Platforms
Market Size & Forecast (2023-2030), By Application,
USD Million
- Disease
Diagnosis
- Monitoring
& Management
- Drug
Development & Clinical Trials
- Predictive
Risk Analysis
- Behavioural
& Cognitive Assessment
- Others
Market Size & Forecast (2023-2030), By Therapeutic
Area, USD Million
- Neurological
Disorders
- Cardiovascular
Diseases
- Diabetes
& Metabolic Disorders
- Respiratory
Diseases
- Psychiatric
& Behavioural Health
- Sleep
Disorders
- Others
Market Size & Forecast (2023-2030), By End User, USD
Million
- Pharmaceutical
& Biotech Companies
- Healthcare
Providers
- Healthcare
Payers
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights
firm. Our clients include Fortune 500 companies, blue-chip investors &
hyper-growth start-ups. We have completed 100+ projects in Digital Health,
Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the
areas of market assessments, due diligence, competitive intelligence, market
sizing and forecasting, pricing analysis & go-to-market strategy. Our
methodology includes rigorous secondary research combined with deep-dive
interviews with industry-leading CXO, VPs, and key demand/supply side
decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment